Related references
Note: Only part of the references are listed.Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses
Nathaniel Hendrix et al.
MEDICAL DECISION MAKING (2021)
Distributional Cost-Effectiveness Analysis Comes of Age
Richard Cookson et al.
VALUE IN HEALTH (2021)
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
Florian Zeevat et al.
VALUE IN HEALTH (2021)
Economic evaluation of nurse-led stroke aftercare addressing long-term psychosocial outcome: a comparison to care-as-usual
Daan P. J. Verberne et al.
BMJ OPEN (2021)
Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States
Richard Z. Xie et al.
PHARMACOECONOMICS (2021)
Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey
Joanna C. Thorn et al.
VALUE IN HEALTH (2021)
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia
Youngji Jo et al.
PLOS ONE (2021)
Cost-Utility Analysis of Anterior Vertebral Body Tethering versus Spinal Fusion in Idiopathic Scoliosis from a US Integrated Healthcare Delivery System Perspective
David W. Polly et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2021)
Micro-costing in health and medicine: a critical appraisal
Xiao Xu et al.
HEALTH ECONOMICS REVIEW (2021)
Developing a Framework for Public Involvement in Mathematical and Economic Modelling: Bringing New Dynamism to Vaccination Policy Recommendations
Sophie Staniszewska et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2021)
Involving Patients in Health Economics Research: The PACTS Principles
Annie Hawton et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2021)
Equity-Efficiency Trade-offs Associated With Alternative Approaches to Deceased Donor Kidney Allocation: A Patient-level Simulation
Bernadette Li et al.
TRANSPLANTATION (2020)
Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
T. Joseph Mattingly et al.
PHARMACOECONOMICS (2020)
Cost-effectiveness of a specialist smoking cessation package compared with standard smoking cessation services for people with severe mental illness in England: a trial-based economic evaluation from the SCIMITAR plus study
Jinshuo Li et al.
ADDICTION (2020)
Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis
Ferran Catala-Lopez et al.
BMJ OPEN (2020)
Economic evaluation of the OSAC randomised controlled trial: oral corticosteroids for non-asthmatic adults with acute lower respiratory tract infection in primary care
Aida Moure-Fernandez et al.
BMJ OPEN (2020)
Growth and capacity for cost-effectiveness analysis in Africa
Ari D. Panzer et al.
HEALTH ECONOMICS (2020)
Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report
Daniel C. Malone et al.
VALUE IN HEALTH (2020)
Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis
Jesse Elliott et al.
PHARMACOECONOMICS (2020)
Principles for deliberative processes in health technology assessment
Kenneth Bond et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2020)
Reporting guidelines of health research studies are frequently used inappropriately
Lisa Caulley et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2020)
Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset Clostridioides difficile Infection
Anna K. Barker et al.
JAMA NETWORK OPEN (2020)
Impact of Socioeconomic Differences on Distributional Cost-effectiveness Analysis
Fan Yang et al.
MEDICAL DECISION MAKING (2020)
Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts
Anne M Neilan et al.
CLINICAL INFECTIOUS DISEASES (2020)
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018
David D. Kim et al.
PHARMACOECONOMICS (2020)
Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative
Lucinda S. Orsini et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist
Jean-Paul Salameh et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
Florian M Marx et al.
Lancet Global Health (2020)
Using Revealed Preference Methods to Estimate the Value of Reduced Mortality Risk: Best Practice Recommendations for the Hedonic Wage Model
Mary F. Evans et al.
REVIEW OF ENVIRONMENTAL ECONOMICS AND POLICY (2020)
Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model
Ingrid E. H. Kremer et al.
MEDICAL DECISION MAKING (2020)
A general framework for classifying costing methods for economic evaluation of health care
Zuzana Spacirova et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
Cost-effectiveness of a non-pharmacological treatment vs. care as usual in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controlled DeTaMAKS-trial
Kathrin Steinbeisser et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report
John Brazier et al.
VALUE IN HEALTH (2019)
SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education): Publication Guidelines for Educational Improvement
Greg Ogrinc et al.
ACADEMIC MEDICINE (2019)
Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK
Samik Datta et al.
BMC INFECTIOUS DISEASES (2019)
Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study
S. M. Niaz Arifin et al.
MEDICAL DECISION MAKING (2019)
Adherence to the iDSI reference case among published cost-per-DALY averted studies
Joanna Emerson et al.
PLOS ONE (2019)
Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project
Jeroen P. Jansen et al.
PHARMACOECONOMICS (2019)
A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist-Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH)
Helen Tam-Tham et al.
VALUE IN HEALTH (2019)
Current UK Practices on Health Economics Analysis Plans (HEAPs): Are We Using Heaps of Them?
Melina Dritsaki et al.
PHARMACOECONOMICS (2018)
Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial
J. M. Mason et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
The Future of Precision Medicine: Potential Impacts for Health Technology Assessment
James Love-Koh et al.
PHARMACOECONOMICS (2018)
Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks
Minah Park et al.
BMC MEDICINE (2018)
Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina
Federico Augustovski et al.
VALUE IN HEALTH (2018)
Reviewing progress in public involvement in NIHR research: developing and implementing a new vision for the future
Sophie Staniszewska et al.
BMJ OPEN (2018)
Economic Analysis of Vaccination Programs
Josephine Mauskopf et al.
VALUE IN HEALTH (2018)
Benefits, Challenges and Potential Strategies of Open Source Health Economic Models
William C. N. Dunlop et al.
PHARMACOECONOMICS (2017)
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial
[Anonymous]
HEALTH TECHNOLOGY ASSESSMENT (2017)
CONTRIBUTION OF STAKEHOLDER ENGAGEMENT TO THE IMPACT OF A HEALTH TECHNOLOGY ASSESSMENT: AN IRISH CASE STUDY
Mairin Ryan et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2017)
Constrained Optimization Methods in Health Services Research-An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force
William Crown et al.
VALUE IN HEALTH (2017)
Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding
Daoud Al-Badriyeh et al.
BMJ OPEN (2017)
The influence of time horizon on results of cost-effectiveness analyses
David D. Kim et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2017)
Potential sponsorship bias in cost-effectiveness analyses of healthcare interventions: A cross-sectional analysis
Ferran Catala-Lopez et al.
ATENCION PRIMARIA (2017)
AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
P. Vemer et al.
PHARMACOECONOMICS (2016)
The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling
George A. K. van Voorn et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2016)
Recommendations for the Conduct and Reporting of Modeling and Simulation Studies in Health Technology Assessment
Issa J. Dahabreh et al.
ANNALS OF INTERNAL MEDICINE (2016)
Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature
Catherine Pitt et al.
HEALTH ECONOMICS (2016)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
A history of the evolution of guidelines for reporting medical research: the long road to the EQUATOR Network
Douglas G. Altman et al.
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2016)
HEALTH ECONOMICS ANALYSIS PLANS: WHERE ARE WE NOW?
J. C. Thorn et al.
VALUE IN HEALTH (2016)
The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought
Thomas Wilkinson et al.
VALUE IN HEALTH (2016)
Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force
A. Brett Hauber et al.
VALUE IN HEALTH (2016)
Towards a common standard - A reporting checklist for web-based stated preference valuation surveys and a critique for mode surveys
N. Menegaki Angeliki et al.
JOURNAL OF CHOICE MODELLING (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement
Lesley A. Stewart et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)
Feng Xie et al.
PHARMACOECONOMICS (2015)
Adapting the CHEERS Statement for Reporting Cost-Benefit Analysis
Sabina Sanghera et al.
PHARMACOECONOMICS (2015)
Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice
James F. O'Mahony et al.
PHARMACOECONOMICS (2015)
The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration
Stavros Petrou et al.
PHARMACOECONOMICS (2015)
Criteria for Reporting the Development and Evaluation of Complex Interventions in healthcare: revised guideline (CReDECI 2)
Ralph Moehler et al.
TRIALS (2015)
The Changing Face of the Cost-Utility Literature, 1990-2012
Peter J. Neumann et al.
VALUE IN HEALTH (2015)
Cost-Effectiveness Analysis Alongside Clinical Trials II-An ISPOR Good Research Practices Task Force Report
Scott D. Ramsey et al.
VALUE IN HEALTH (2015)
STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
Patrick M. Bossuyt et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement
Eric I. Benchimol et al.
PLOS MEDICINE (2015)
STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
Patrick M. Bossuyt et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
The Development of Capability Measures in Health Economics: Opportunities, Challenges and Progress
Joanna Coast et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2015)
Mapping the impact of patient and public involvement on health and social care research: a systematic review
Jo Brett et al.
HEALTH EXPECTATIONS (2014)
Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Sean D. Sullivan et al.
VALUE IN HEALTH (2014)
Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
Tammy C. Hoffmann et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
A Systematic Review of the Impact of Patient and Public Involvement on Service Users, Researchers and Communities
Jo Brett et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2014)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
D. Husereau et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Don Husereau et al.
BMC MEDICINE (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Don Husereau et al.
CLINICAL THERAPEUTICS (2013)
CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT
Don Husereau et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2013)
When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins
Ferran Catala-Lopez et al.
PLOS ONE (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Don Husereau et al.
PHARMACOECONOMICS (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
Don Husereau et al.
VALUE IN HEALTH (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Don Husereau et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Don Husereau et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2013)
An assessment of the construct validity of the ASCOT measure of social care-related quality of life with older people
Juliette N. Malley et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2012)
Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
David M. Eddy et al.
MEDICAL DECISION MAKING (2012)
Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
Andrew H. Briggs et al.
VALUE IN HEALTH (2012)
Inquiry into the Relationship between Equity Weights and the Value of the QALY
Ana Bobinac et al.
VALUE IN HEALTH (2012)
Modeling Good Research Practices-Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
J. Jaime Caro et al.
VALUE IN HEALTH (2012)
Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
David M. Eddy et al.
VALUE IN HEALTH (2012)
Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test
Nikolaos P. Polyzos et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2011)
Guidelines for conducting and reporting economic evaluation of fall prevention strategies
J. C. Davis et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
David C. Hoaglin et al.
VALUE IN HEALTH (2011)
Conjoint Analysis Applications in Health-a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
John F. P. Bridges et al.
VALUE IN HEALTH (2011)
Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting
Stavros Petrou et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting
Stavros Petrou et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
Sekwon Jang et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Modeling in pharmacoeconomic studies: Funding sources and outcomes
Livio Garattini et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2010)
Classification of evidence in decision-analytic models of cost-effectiveness: A content analysis of published reports
Suzy Paisley
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2010)
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report-Part I
Joel W. Hay et al.
VALUE IN HEALTH (2010)
Guidance for Developers of Health Research Reporting Guidelines
David Moher et al.
PLOS MEDICINE (2010)
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses
Xin Sun et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Uniform format for disclosure of competing interests in ICMJE journals
Jeffrey M. Drazen et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
Borislave Mihaylova et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2009)
Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines
Natasha K. Stout et al.
PHARMACOECONOMICS (2009)
Dealing with heterogeneity of treatment effects: is the literature up to the challenge?
Nicole B. Gabler et al.
TRIALS (2009)
Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
Michael Drummond et al.
VALUE IN HEALTH (2009)
Explicit incorporation of equity considerations into economic evaluation of public health interventions
Richard Cookson et al.
HEALTH ECONOMICS POLICY AND LAW (2009)
Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications
Mireille M Goetghebeur et al.
BMC HEALTH SERVICES RESEARCH (2008)
Modelling methods for pharmacoeconomics and health technology assessment - An overview and guide
James E. Stahl
PHARMACOECONOMICS (2008)
Subgroups and heterogeneity in cost-effectiveness analysis
Mark Sculpher
PHARMACOECONOMICS (2008)
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration
Jan P. Vandenbroucke et al.
ANNALS OF INTERNAL MEDICINE (2007)
Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration
Jan P. Vandenbroucke et al.
PLOS MEDICINE (2007)
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20 536 people
Borislava Mihaylova et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
A taxonomy of model structures for economic evaluation of health technologies
Alan Brennan et al.
HEALTH ECONOMICS (2006)
Bias in published cost effectiveness studies: systematic review
CM Bell et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Subgroup analyses in therapeutic cardiovascular clinical trials:: Are most of them misleading?
AV Hernández et al.
AMERICAN HEART JOURNAL (2006)
Cost-of-illness analysis - What room in health economics?
R Tarricone
HEALTH POLICY (2006)
Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies
M Drummond et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2005)
Translation and validation of study instruments for cross-cultural research
AD Sperber
GASTROENTEROLOGY (2004)
Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics
AM Vintzileos et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2004)
What should be reported in a methods section on utility assessment?
PFM Stalmeier et al.
MEDICAL DECISION MAKING (2001)
Assessing quality in decision analytic cost-effectiveness models - A suggested framework and example of application
M Sculpher et al.
PHARMACOECONOMICS (2000)
Subgroup analysis and other (mis)uses of baseline data in clinical trials
SF Assmann et al.
LANCET (2000)
Share Paper
